Literature DB >> 1380407

Biochemical modulation of 5-fluorouracil with or without leucovorin by a low dose of brequinar in MGH-U1 cells.

T L Chen1, C Erlichman.   

Abstract

Combination of low doses of de novo pyrimidine biosynthesis inhibitors with 5-fluorouracil (FU) has been proposed to increase the antitumor activity of FU. Brequinar is such an inhibitor that has little clinical anti-tumor effect when used alone. We determined the clonogenic survival of MGH-U1 cells treated with FU +/- leucovorin (LV) +/- brequinar and examined the effects of these treatments on thymidylate synthase (TS). After 24 h exposure, the concentrations resulting in 50% inhibition of cell growth (IC50) for brequinar, FU, and FU+LV (100 microM) were 0.4, 20, and 10 microM, respectively. Both 24 h pretreatment and 48 h continuous treatment with the IC10 (0.1 microM) of brequinar increased the cytotoxicity of FU but did not enhance that of FU+LV. Simultaneous 24 h exposure to 0.1 microM brequinar and FU +/- LV did not increase the cytotoxicity of FU +/- LV. Intracellular cytidine triphosphate (CTP) and uridine triphosphate (UTP) pools, free TS binding sites, and levels of free fluorodeoxyuridine monophosphate (FdUMP) and deoxyuridine monophosphate (dUMP) were measured in cells pretreated with 0.1 microM brequinar for 24 h alone or followed by a 2-h exposure to FU (25 microM) +/- LV (100 microM). In brequinar-treated cells, CTP and UTP pools amounted to 68% and 46% of control values, respectively. The free TS binding sites remaining amounted to 70% of control values in cells treated with FU and 9% of control levels in those treated with FU+brequinar. Free FdUMP levels increased 5-fold in cells pretreated with brequinar as compared with those treated with FU alone. The increased formation of FdUMP was inhibited by simultaneous exposure to 100 microM hypoxanthine and 25 microM FU. Intracellular dUMP levels were not affected by brequinar. We conclude that a low dose of brequinar increases the cytotoxicity of FU but does not enhance that of FU+LV when exposure to brequinar precedes FU treatment. This potentiation appears to be mediated by the increased formation of FdUMP as a consequence of an increase in the cosubstrate phosphoribosyl pyrophosphate (PRPP).

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1380407     DOI: 10.1007/bf00689965

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  38 in total

1.  Inhibition of pyrimidine de novo synthesis by DUP-785 (NSC 368390).

Authors:  G J Peters; S L Sharma; E Laurensse; H M Pinedo
Journal:  Invest New Drugs       Date:  1987       Impact factor: 3.850

2.  Fluorouracil and leucovorin for metastatic colorectal cancer.

Authors:  C Erlichman
Journal:  J Chemother       Date:  1990-02       Impact factor: 1.714

Review 3.  Biochemical rationale for the 5-fluorouracil leucovorin combination and update of clinical experience.

Authors:  Y M Rustum
Journal:  J Chemother       Date:  1990-02       Impact factor: 1.714

4.  An isotopic assay for thymidylate synthetase.

Authors:  D Roberts
Journal:  Biochemistry       Date:  1966-11       Impact factor: 3.162

5.  A phase I clinical and pharmacokinetic study of Brequinar sodium, DUP 785 (NSC 368390), using a weekly and a biweekly schedule.

Authors:  E Bork; S Vest; H H Hansen
Journal:  Eur J Cancer Clin Oncol       Date:  1989-10

6.  The relation between inhibition of cell growth and of dihydroorotic acid dehydrogenase by brequinar sodium.

Authors:  E de Kant; H M Pinedo; E Laurensse; G J Peters
Journal:  Cancer Lett       Date:  1989-07-15       Impact factor: 8.679

7.  Activity of a novel 4-quinolinecarboxylic acid, NSC 368390 [6-fluoro-2-(2'-fluoro-1,1'-biphenyl-4-yl)-3-methyl-4-quinolinecarb oxylic acid sodium salt], against experimental tumors.

Authors:  D L Dexter; D P Hesson; R J Ardecky; G V Rao; D L Tippett; B A Dusak; K D Paull; J Plowman; B M DeLarco; V L Narayanan
Journal:  Cancer Res       Date:  1985-11       Impact factor: 12.701

8.  Sensitivity of human, murine, and rat cells to 5-fluorouracil and 5'-deoxy-5-fluorouridine in relation to drug-metabolizing enzymes.

Authors:  G J Peters; E Laurensse; A Leyva; J Lankelma; H M Pinedo
Journal:  Cancer Res       Date:  1986-01       Impact factor: 12.701

9.  Mechanisms of innate resistance to thymidylate synthase inhibition after 5-fluorouracil.

Authors:  C P Spears; B G Gustavsson; M Berne; R Frösing; L Bernstein; A A Hayes
Journal:  Cancer Res       Date:  1988-10-15       Impact factor: 12.701

Review 10.  Clinical pharmacology of 5-fluorouracil.

Authors:  R B Diasio; B E Harris
Journal:  Clin Pharmacokinet       Date:  1989-04       Impact factor: 6.447

View more
  1 in total

1.  Comparative cytotoxicity of folate-based inhibitors of thymidylate synthase and 5-fluorouracil +/- leucovorin in MGH-U1 cells.

Authors:  C Erlichman; B Mitrovski
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.